CJC-1295 no DAC + Ipamorelin 10mg

It is a single vial containing both CJC-1295 No DAC and Ipamorelin, supplied as a lyophilised powder. You will see it written CJC 1295 Ipamorelin, CJC-1295 + Ipamorelin, or CJC 1295 no DAC Ipamorelin 10mg blend — all describe the same dual-peptide research preparation.

Yes. Mod GRF 1-29 is another name for CJC-1295 No DAC, so "Mod GRF 1-29 and Ipamorelin" describes exactly this product. You will also see it shortened to CJC + Ipa, or written CJC 1295 Ipa.

This blend uses the No DAC form of CJC-1295, which clears within hours. The DAC version carries a Drug Affinity Complex that binds albumin and persists for around a week — a different molecule with different handling. Blends listed simply as "CJC-1295 + Ipamorelin" do not always state which form they contain; this one is No DAC.

PhaseOne ships this blend Australia-wide for research use, dispatched locally with tracking, in 10mg vials. Every vial carries a batch-specific Certificate of Analysis verifying ≥99% HPLC purity for both components.

Yes — PhaseOne has the CJC 1295 Ipamorelin blend for sale online in 10mg vials, shipped Australia-wide. Two things worth checking on any blend listing: which CJC-1295 form it contains, and whether the Certificate of Analysis covers both peptides rather than just one. Every PhaseOne batch is tested for both.

PhaseOne prices the CJC-1295 + Ipamorelin blend at A$87.99 for the 10mg vial, with the batch Certificate of Analysis included at no extra cost.

The blend arrives pre-combined in fixed proportions and needs reconstituting once, which suits research designs using both peptides at a set ratio. Separate vials cost more in total but let each be varied independently. (!) View CJC-1295 No DAC and Ipamorelin individually.

No. Neither CJC-1295 nor Ipamorelin is registered on the ARTG or approved for supply as a medicine in Australia, so Chemist Warehouse and other Australian chemists do not stock either. Both are supplied as research compounds through research suppliers instead.

Researchers across Australia studying GH-axis pathways often examine CJC-1295 and Ipamorelin together, since each targets a different but complementary receptor in the growth hormone secretion pathway. (!) Learn more in our CJC-1295 + Ipamorelin peptide guide view here.

CJC-1295 No DAC is a synthetic GHRH analogue studied for stimulating growth hormone release via the GHRH receptor, without the DAC modification that extends half-life in the original CJC-1295 compound. (!) Read more here: CJC-1295 No DAC.

Ipamorelin is studied as a highly selective ghrelin receptor (GHS-R) agonist, valued in research contexts for stimulating growth hormone release with minimal effect on cortisol or prolactin compared to older secretagogues. (!) Read more here: Ipamorelin.

This blend should be stored refrigerated, unreconstituted, and protected from light, in line with standard practice across Australian peptide research. It is commonly reconstituted with bacteriostatic water prior to research use. (!) Read our reconstitution guide.

Every batch of this blend sold across Australia is independently HPLC tested, with a Certificate of Analysis verifying both peptide components.

Yes - researchers studying GH-axis pathways may also look at HGH 191AA or IGF-1 LR3 as downstream or adjacent research compounds in the same pathway. (!) View our growth hormone peptide guide for the full research category.